From the initial discovery in 2005 [5], the TMPRSS2- ERG gene fusion has been linked to clinical outcome parameters such as early onset of prostate cancer [6], negative outcome in watchful waiting patients [7–9] and a higher risk of disease progression in active surveillance patients [10]. Here, ERG is linked to prostate carcinoma.